Sight Sciences Inc SGHT released the six-month SAHARA randomized controlled trial comparing interventional eyelid procedures enabled by TearCare Technology to Restasis for dry eye disease. TearCare is ...

MENLO PARK, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing ...

Please provide your email address to receive an email when new articles are posted on . WAILEA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2024, Jennifer Loh, MD, explains the results ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window We all know that ...

MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing ...

(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX) on Tuesday announced that the U.S. Food and Drug Administration has approved its cyclosporine ophthalmic emulsion 0.05%, a sterile formulation supplied ...

Dear Dr Roach: I developed chronic dry eyes after having cataract surgery on both eyes. I consulted an ophthalmologist who specialized in treating dry eyes. She prescribed Restasis, but my condition ...

Burning, itching, watering eyes. Few things are a bigger nuisance than irritated eyes, so it's no surprise there are so many options for dry eye relief. While various treatment options are available ...

MENLO PARK, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing ...

Patients treated with a single interventional eyelid procedure enabled by TearCare® technology after receiving Restasis® for the first six months of the trial realized clinically meaningful ...